Initiation of ivabradine in cardiogenic shock

ConclusionsIn our small non ‐randomized series of patients in cardiogenic shock, ivabradine was safely used to reduce HR in patients previously intolerant of beta‐blockade. There are limited data surrounding the use of ivabradine in cardiogenic shock, and future studies should be undertaken to determine the optimal HR in h umans with cardiogenic shock and whether systematic limitation of peak HR may improve outcomes.

Source: ESC Heart Failure - July 22, 2019 Category: Cardiology Authors: Michael H. Chiu, Jonathan G. Howlett, Nakul C. Sharma Tags: Short Communication Source Type: research